Co­herus warns of lim­it­ed can­cer drug sup­ply due to third-par­ty ‘ca­pac­i­ty con­straints’

Sup­plies of Co­herus Bio­sciences’ biosim­i­lar ver­sion of the white blood cell-stim­u­lat­ing drug Neu­las­ta will be “sub­stan­tial­ly de­plet­ed” through mid-Oc­to­ber be­cause of pro­duc­tion con­straints at a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER